Sydney E S Brown, Graciela Mentz, Ruth Cassidy, Meridith Wade, Xinyue Liu, Wenjun Zhong, Julia DiBello, Rebecca Nause-Osthoff, Sachin Kheterpal, Douglas A Colquhoun
BACKGROUND: Sugammadex was initially approved for reversal of neuromuscular blockade in adults in the United States in 2015. Limited data suggest sugammadex is widely used in pediatric anesthesia practice however the factors influencing use are not known. We explore patient, surgical, and institutional factors associated with the decision to use sugammadex versus neostigmine or no reversal, and the decision to use 2 mg/kg vs 4 mg/kg dosing. METHODS: Using data from the Multicenter Perioperative Outcomes Group (MPOG) database, an EHR-derived registry, we conducted a retrospective cross-sectional study...
January 19, 2024: Anesthesia and Analgesia